Trial Profile
A phase II study assessing safety and human efficacy of Silmitasertib in treating COVID-19 in Taiwan
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2023
Price :
$35
*
At a glance
- Drugs Silmitasertib (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Senhwa Biosciences
- 09 Nov 2023 According to Senhwa Biosciences media release, the study is conducted in National Cheng Kung University Hospital.
- 09 Nov 2023 According to Senhwa Biosciences media release, first patient has been dosed.
- 09 Nov 2023 Status changed from planning to recruiting.